🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Business news, market intelligence, and global industry analysis.
The Latest

Zydus Lifesciences gets FDA approval for Bortezomib for Injection

bySrinath
May 3, 2022
Total
0
Shares
0
0
0

Zydus Lifesciences (previously called Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) to market Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial.

Bortezomib for Injection is the generic of Velcade (bortezomib), which has a market size of $1.17bn as per IQVIA MAT March 2022.

It is used for the treatment of some forms of cancer that include multiple myeloma and mantle cell lymphoma.

The drug works by either slowing or stopping the growth of cancer cells.

Zydus Lifesciences gets FDA approval for Bortezomib for Injection
Zydus Lifesciences gets FDA approval for Bortezomib for Injection. Photo courtesy of Zydus Cadila.

Bortezomib for Injection will be manufactured at Zydus Hospira.

Zydus Lifesciences currently has 331 approvals and till now has submitted more than 400 abbreviated new drug applications (ANDAs) since the start of filing process in FY 2003-04.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Cumberland Pharmaceuticals announces FDA approval for Acetadote's simplified dosing regimen
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cutera truSculpt iD body sculpting treatment gets expanded approval in Canada

Cutera said that Health Canada has expanded approval for its truSculpt iD body sculpting treatment to cover its use for the reduction of circumference of the abdomen and non-invasive lipolysis, which is the permanent removal of fat cells from the body. According to American Society for Aesthetic Plastic Surgery and Medical Insight (MII), noninvasive body sculpting […]

The post Cutera truSculpt iD body sculpting treatment gets expanded approval in Canada appeared first on PharmaNewsDaily.com.

bypharmanewsdaily
Read More

Boehringer Ingelheim, Inflammasome to advance new therapies for retinal diseases

German pharma giant Boehringer Ingelheim has entered into a co-development and license agreement with US-based Inflammasome Therapeutics to develop new retinal disease therapies and reduce the patient burden for eye diseases. The company is planning to develop up to three therapies for patients with retinal diseases by integrating its retinal disease pipeline portfolio compounds with […]

The post Boehringer Ingelheim, Inflammasome to advance new therapies for retinal diseases appeared first on PharmaNewsDaily.com.

bySrinath